Cyclerion Therapeutics is a biopharmaceutical company that focuses on developing drugs to treat severe central nervous system diseases. Its primary drug in development is CY6463, which is currently undergoing Phase IIa trials that aim to treat mitochondrial encephalomyopathy and Alzheimer's disease, among other conditions. Alongside CY6463, the company is also developing Praliciguat and Olinciguat, which are undergoing Phase II trials for resistant hypertension, diabetic nephropathy, and sickle cell disease.